MSLN and pancreatic neoplasm: Notably, core fucosylated MSLN (Cf-MSLN) was found to be reduced in tumor tissues and serum compared to healthy controls, suggesting its potential as a more specific biomarker for pancreatic cancer than total MSLN levels.